REYKJAVÍK, ICELAND, 4 SEPTEMBER, 2015 – Oculis has been awarded a research grant from the Technology Development Fund. The Technology Development Fund is a competitive fund which issues its calls for proposals twice a year. The role of the fund is to support research and development activities, which aim towards innovation in Icelandic industry.
The Technology Development Fund is managed by The Icelandic Centre for Research (RANNIS). RANNIS supports research, innovation, education and culture in Iceland. RANNIS cooperates closely with the Icelandic Science and Technology Policy Council and provides professional assistance in the preparation and implementation of the national science and technology policy. RANNIS administers competitive funds in the fields of research, innovation, education and culture, as well as strategic research programmes. Further information on RANNIS, can be found on en.rannis.is.
Oculis is a clinical-stage, privately held, pharmaceutical development company focusing on ophthalmic drugs and novel drug delivery to the eye. Oculis has developed a drug delivery platform consisting of a novel technique to facilitate drug absorption to both anterior and posterior parts of the eye. The advantage is a drug delivery system where diseases of the posterior part of the eye can be treated with a simple topical application, i.e. an eye drop.
For further information on Oculis, please visit: http://www.oculispharma.com.